Companies
Dr. Falk Pharma
funded university research (Tampere University, University of Oulu) on ZED1227, an oral TG2 inhibitor that in a 2024 study protected patients consuming 3 grams of daily gluten for six weeks from measurable intestinal mucosal damage and inflammation at a 100 mg daily dose,…
- Country
- Germany
Coverage
| CN | EU | US | |
|---|---|---|---|
| food-alt-protein | ✓ | ✓ | ✓ |
Regulatorsemafda
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Dr. Falk Pharma funded university research (Tampere University, University of Oulu) on ZED1227. | researchportal.tuni.fi · isrctn.com · news-medical.net · oulu.fi · tuni.fi |
| Funding | Dr. Falk Pharma and Zedira collaborated on ZED1227 with Takeda, involving upfront payments and milestones. | htgf.de · zedira.com |
| Headcount | Approximately 1,000 to 1,198 employees globally (1,198 as of 2023). | compworth.com · htgf.de · listenchampion.de |
| Headquarters | Freiburg, Germany. | compworth.com · htgf.de · zedira.com |
| Production site | Europe, mainly at sites in Germany, France, Italy, and Switzerland. | compworth.com · htgf.de · zedira.com |
| Revenue | 499 million Euros (as of 2023). | listenchampion.de |
| Certification | EU-GMP certified facilities. medium confidence | chemdmart.com |
Independent sources: chemdmart.com · compworth.com · htgf.de · isrctn.com · listenchampion.de · news-medical.net · oulu.fi · researchportal.tuni.fi · tuni.fi · zedira.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Enzymatic therapy for celiac | food-alt-protein | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.